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Poor quality medicines represent an expanding global public health threat facilitated 1 
by the Internet. A recent survey showed that one in five students have used modafinil 2 
to enhance learning ability mainly purchased from Internet sources. The aim of this 3 
work was to develop on-the-spot and simple methods for the quantification of modafinil 4 
in generic medicines using Fourier transform-infrared (FTIR), near-infrared (NIR) and 5 
Raman spectroscopy along with partial least square regression (PLSR). Modafinil 6 
tablets were measured in intact form using NIR and Raman and in powdered form 7 
using FTIR, NIR and Raman. Additionally, powder mixtures of crushed modafinil 8 
tablets and excipient(s) were prepared either by diluting the crushed tablets with 9 
excipient(s), or sequentially adding excipient(s) to the crushed tablets. Three PLSR 10 
models were constructed in Matlab 2014a from powder mixtures and two from intact 11 
and powdered tablets. For FTIR and Raman spectroscopy, PLSR models based on 12 
tablets gave linear calibration curve with correlation coefficient (r2) values above 0.94 13 
and a root mean square error of calibration (RMSEC) below 0.96% m/m. Conversely, 14 
the PLSR model based on powder sequential addition gave the highest accuracy using 15 
the NIR spectra (r2 = 0.99, RMSEC = 1.15% m/m). The latter model showed accuracy 16 
in predicting the concentration of the active pharmaceutical ingredient in modafinil 17 
generic medicines proving their authenticity. The overall results showed that the 18 
combination of the three spectroscopic methods with PLSR offered a rapid technique 19 
for authenticating generic modafinil medicines. 20 
 21 
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1. Introduction 25 
Poor quality medicines represent a global threat to the public health that can result in 26 
treatment ineffectiveness, drug resistance, increased morbidity and mortality rate, 27 
economic loss and problems to the healthcare system [1,2]. Poor quality medicines 28 
can be degraded, substandard or counterfeit medicines [3]. Degraded medicines 29 
include those, which deteriorate from the poor-quality storage (humidity, temperature 30 
and light). Substandard medicines are those that encounter accidental defects in the 31 
manufacturing process and fail to fulfil the products’ specifications. Counterfeit 32 
medicines are medicines which “are deliberately and fraudulently mislabelled with 33 
respect to identity and/or source” [4]. 34 
The Internet plays a major role in the spread of poor quality medicines, which could 35 
be over the counter products, prescription medicines, drugs of abuse and 36 
supplementary products [5-7]. This is partly due to the fact that the market of 37 
counterfeit online medicines is in continuous expansion [8]. According to the World 38 
Health Organisation (WHO), 50% of the medicines sold through illegal online 39 
pharmacies are counterfeits [9]. Thus, in 2013 the Interpol closed down over 9600 40 
illegal online pharmacies and seized over 9.6 million prescription medicines that were 41 
worth over $41.1 million [10]. In this respect, the purchase of a counterfeit medicine 42 
could impose a public safety issue especially in case of drugs of abuse where 43 
medicines are frequently bought. 44 
Smart drugs were one of the top classes that sales have increased (up to 50%) over 45 
the last decade and has been facilitated by the Internet (International Narcotics Control 46 
Board, 2016). Smart Drugs such include nootropics that have become particularly 47 
popular among students and healthcare professionals who have been under pressure 48 
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of study/work [11,12].  Students and healthcare professionals have utilised nootropics 49 
for enhancement of the memory and learning abilities [13-15]. There are several 50 
different nootropics on the market e.g. adderall, dexedrine, ephedrine, 51 
methylphenidate, modafinil and piracetam. Modafinil has the same stimulant effects of 52 
nootropics however it has less abusive tendencies and side effects [13,14].  53 
Modafinil is sold under the brand name Provigil [16], and comprises modafinil as the 54 
active pharmaceutical ingredient (API), and the following excipients: croscarmellose 55 
sodium, lactose monohydrate, magnesium stearate, maize starch and povidone. 56 
Nonetheless, the excipients in generic modafinil are not always known and this 57 
variation influences the process of authentication of branded and generic modafinil. 58 
Thus, when authenticating a branded medicine, the test medicine needs to match the 59 
physical and chemical properties of the reference medicine [17]. Generic medicines 60 
however only need to prove that they contain the exact API at the correct concentration 61 
in relation to the reference medicine [18]. Consequently, a quantitative approach in 62 
authenticating generic modafinil medicines is favoured. 63 
The literature reported conventional methods for quantification of the API in modafinil, 64 
which range from simple spectrophotometric to chromatographic methods. A 65 
spectrophotometric method was reported for the quantification of modafinil in solid 66 
dosage forms and underlined measurement of the absorbance of modafinil at its 67 
maximum wavelength (236 nm) [19]. Chromatographic methods utilised mainly 68 
reverse phase high performance liquid chromatography (RP-HPLC) [19-22], and thin 69 
layer chromatography (TLC) [23]. The aforementioned techniques offered, sensitivity, 70 
selectivity and precision yet they were time-consuming, destructive and required 71 
extensive sample preparation. On the contrary, spectroscopic techniques including 72 
Fourier transform infrared (FTIR), near-infrared (NIR) and Raman spectroscopy have 73 
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shown to be quicker, simpler and mobile [24-33]. When combined with multivariate 74 
regression analysis spectroscopic techniques offered rapid, on-spot and non-75 
destructive quantification of APIs medicines [17,32]. To the best of our knowledge, no 76 
spectroscopic methods have yet been employed for quantification of modafinil in 77 
tablets. 78 
Therefore, this work aimed at developing methods for the on-spot quantification of 79 
modafinil in generic medicines using FTIR, NIR and Raman spectroscopy along with 80 
PLSR.  81 
 82 
2. Materials and Methods 83 
2.1. Materials 84 
Standard reference material including glucose, lactose, magnesium stearate, 85 
maize starch, microcrystalline cellulose, modafinil, povidone, sodium 86 
carboxymethylcellulose and sucrose were purchased from Sigma-Aldrich. 87 
Eight modafinil generic batches of doses 100 and 200 milligrams (mgs) were 88 
bought from four Internet websites (Table 1). The percentage mass per mass (% 89 
m/m) of modafinil in the tablets was in the range of 57.6 – 72.7% m/m.  90 
Reference analysis of modafinil API and tablets was performed using reverse 91 
phase-high performance liquid chromatography (RP-HPLC) by adopting the 92 






2.2. Sample Preparation 97 
Four types of samples were considered in this study. The first type included intact 98 
tablets, which were removed from the packaging and used ‘as received’ without 99 
any treatment. The second type comprised powdered tablets which had been 100 
crushed in a mortar, homogenised and stored in 4 mm glass vials. The third type 101 
of samples comprised powders of pure substances (API and excipients) and the 102 
fourth type included powdered mixtures that were prepared by mixing crushed 103 
modafinil tablets with excipient(s).  104 
Three modafinil mixtures were prepared and included: M1 (modafinil lactose 105 
dilution), M2 (modafinil excipients dilution) and M3 (modafinil excipients sequential 106 
addition) (Table 2). M1 (modafinil lactose dilution) was prepared by adding aliquots 107 
of lactose (major excipient in modafinil tablets) to crushed modafinil tablets to get 108 
a % m/m of modafinil in the range of 9.59 – 62.5% m/m. Similarly, M2 was prepared 109 
by adding aliquots of different excipients (one at a time) to crushed modafinil tablets 110 
to get 15.4 – 52.9% m/m of modafinil. A third approach was adopted in mixtures 111 
(M3) which was made by adding excipients (one at a time) sequentially to aliquots 112 
of crushed modafinil tablets to get 15.9 – 62.5% m/m. 113 
 114 
2.3. Instrumentation 115 
FTIR spectra were recorded using the Bruker Alpha mobile-FTIR equipped with a 116 
single reflection pure diamond attenuated total reflectance (ATR) crystal sample 117 
interface. The spectral range of the instrument was 500 – 6000 cm-1. NIR spectra 118 
were recorded employing the JDSU microNIR 1700 pro-spectrometer equipped 119 
with linear variable filter (LVF) dispersing element and 128-pixel cooled InGaAs 120 
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photodiode array detector. Spectra were measured over the wavelength range of 121 
900 – 1700 nm. Raman spectra were recorded using the Rigaku FirstGuard 122 
handheld Raman spectrometer equipped with 1064 nm laser power, thermoelectric 123 
cooling and charge coupled device detector. Spectra were collected over the 124 
wavenumber range of 250 – 2000 cm-1. 125 
 126 
2.4. Spectroscopic measurements 127 
For FTIR measurements, a few milligrams from powdered samples or pure 128 
substances were measured by placing them in direct contact with the ATR crystal. 129 
Homogeneous preparations of samples were prepared using a Vortex mixer before 130 
each measurement. Four spectra were measured per sample such that a new 131 
aliquot was changed after each measurement. Each spectrum was the sum of 16 132 
scans at a resolution of 4 cm-1. For NIR and Raman measurements, intact tablets 133 
were measured ‘as received’ by placing them in direct contact with the 134 
spectrometers. Four spectra were taken from each tablet on both sides; such as 135 
two spectra were taken from each side rotating the tablet after each measurement. 136 
In addition, powders were measured through glass vials (after mixing with Vortex 137 
mixer) by placing them in direct contact with the instruments. Each spectrum was 138 
the sum of 32 scans for NIR and three scans for Raman respectively. 139 
 140 
2.5. Data treatment 141 
Spectra from the three instruments were exported to Matlab 2014a for analysis. 142 
Spectral pre-treatment was made using multiplicative scatter correction second 143 
derivative (MSC-D1). The similarity between spectra was assessed using 144 
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correlation in wavelength space (CWS) method. In this respect, a correlation 145 
coefficient (r) value greater than or equal to 0.95 showed similarity. In addition, 146 
quantitative models were developed using partial least square regression (PLSR). 147 
PLSR has been considered as ideal in this case where univariate regression had 148 
not been possible. This was because the absorbance and scattering intensities in 149 
FTIR/NIR and Raman differed according to the physicochemical properties of the 150 
measured samples and not proportional to the concentration of the analyte of 151 
interest (Burns and Ciurczak, 2007) [35]. In this respect, PLSR offered a 152 
multivariate approach for quantifying the APIs in the aforementioned products. 153 
PLSR models predicted the concentrations of the different mixtures and/or 154 
products from multiple variables (absorbance intensities of scattering intensities 155 
measured at the full wavelength range). PLSR models find components (latent 156 
variables) in the absorbance and/or scattering intensities that relate to the 157 
concentrations. A PLSR model eventually assigns loadings (small and large) to the 158 
aforementioned latent variables. Latent variables with small loadings are rejected 159 
and vice versa. This is done by finding factors that capture variation among the 160 
data such that each factor is added as one at a time. In this sense, the first factor 161 
capture the highest variance, the second factor the second highest variance and 162 
so on. The following equations illustrate a PLSR model [36-37]: 163 
X = T.P + E 164 
c = T. q + ƒ 165 
Such as  166 
X absorbance or scattering intensities at different wavelengths 167 
c concentrations 168 
q loading vector 169 
T spectral score vector 170 
p spectral loading vector 171 
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3. Results and Discussion 172 
The present study explored a swift quantification of medicines purchased from 173 
several Internet sources using handheld instruments. This was first study that had 174 
utilised quantitative PLSR models (non-destructive) with portable handheld FTIR, 175 
NIR and Raman spectroscopy, as well as a powder form of formulations with FTIR 176 
for the quantification of modafinil in branded and generic tablets. The 177 
aforementioned PLSR models were not limited to conventional dilution models; but 178 
also included more complex mixtures based on standard and sequential additions 179 
of constituents to crushed tablets.   180 
Eight modafinil products (from different batches) were purchased from four 181 
websites. The eight products were selected based on assessing the differences of 182 
authenticity of products between websites as well as within each website. Four of 183 
these products had a label claim of modafinil 100 mg; while the remaining four had 184 
a label claim of modafinil 200 mg. The concentration range of modafinil in the four 185 
products was 57.6 – 72.7% m/m (Table 1). The tablets were compared in relation 186 
to the major constituents (API and excipients) expected to be present in branded 187 
and generic modafinil tablets. Excipients present in branded modafinil tablets 188 
(Provigil) include lactose monohydrate (main excipient), pregelatinised maize 189 
starch, croscarmellose sodium, povidone K29/32 and magnesium stearate [15].  190 
The excipient content of generic tablets may be variable and not always known 191 
[23], therefore additional excipients were measured including glucose, maize 192 
starch, microcrystalline cellulose, sodium carboxymethylcellulose and sucrose. 193 
The spectra of modafinil tablets were compared to the spectra of the API, 194 




3.1. FTIR, NIR and Raman activity of modafinil tablets 197 
Prior to spectral evaluation the FTIR, NIR and Raman activity of modafinil tablets 198 
and their main constituents had been investigated. When comparing the three 199 
spectroscopic techniques in relation to medicines’ identification, it is well known 200 
that APIs are more Raman active whereas excipients are more IR/NIR active 201 
where the Raman activity of excipients is often masked by fluorescence [24]. If the 202 
medicine contains high concentrations of an excipient then the Raman activity of 203 
the medicine could be masked by the fluorescence exhibited by the excipient. One 204 
way of overcoming fluorescence of excipients was by using a longer wavelength 205 
laser such as 1064 nm, and that had been adopted in the current work.  206 
The FTIR, NIR and Raman spectra of the medicinal products were compared to 207 
those of the API (modafinil) and the major excipient (lactose monohydrate) in 208 
modafinil tablets. Modafinil API was present in high amounts in all of the measured 209 
products (57 – 72% m/m) which minimised the effect of the excipients [24]. This 210 
was confirmed in the spectra of modafinil products, its API and lactose using the 211 
three techniques (Fig. 1). In this respect, the modafinil tablets’ spectra showed 212 
representation of the modafinil API rather than lactose. The FTIR spectrum of 213 
modafinil tablet (Fig. 1a) showed higher similarity for the API spectrum (r = 0.95) 214 
than the lactose spectrum (r = 0.82). Likewise the modafinil tablet NIR spectrum 215 
showed higher representation for the API spectrum (r = 0.99) than lactose 216 
spectrum (r = 0.77). The modafinil Raman spectrum showed higher similarity for 217 
the API spectrum (r = 0.95) but dissimilarity to the lactose spectrum (r = 0.01). This 218 
could be attributed to the strong Raman activity of modafinil API that had not been 219 
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affected by the fluorescence of lactose. Subsequently, the high representation of 220 
the API in the tablets’ spectra contributed to the accuracy of quantification of 221 
tablets.  Crushing the tablets into powders was needed to facilitate data collection 222 
and while this process may affect the physical properties of the powder (such as 223 
the particle size), our observations showed that the spectroscopic data were not 224 
affected.  Some properties such as polymorphic nature of API are likely to be 225 
affected if strong physical processing was applied however, in our experiments we 226 
used gentle processing to ensure minimal energy is applied on tablets.  Such 227 
delicate processing avoids any polymorphic changes (such as recrystallization or 228 
amorphous form formation).  The particles should be representative of the tablets 229 
content regardless of the size of generated particles; hence reproducibility was not 230 
affected by sample preparation.  231 
 232 
3.2. PLSR model construction 233 
PLSR was applied to the MSC-D1 FTIR, NIR and Raman spectra over the full 234 
wavenumber/ wavelength in each technique. Four models were created using the 235 
FTIR spectra and five models were created using the NIR and Raman spectra 236 
(Table 3). 237 
FTIR models included: FTIRM1 (modafinil lactose dilution), FTIRM2 (modafinil 238 
excipients dilution), FTIRM3 (modafinil excipients sequential addition) and FTIRM4 239 
(modafinil powdered tablets model). FTIRM1, FTIRM2 and FTIRM3 were 240 
constructed using a calibration validation (C: V) ratio of 2:1. Moreover, the 241 
calibration ranges used were 9.49 – 62.5, 15.4 – 52.9 and 15.9 – 62.5% m/m 242 
11 
 
respectively. The modafinil powdered tablet model (FTIRM4) was constructed with 243 
a C: V ratio of 3:1, four factors and a range of 54.9 – 62.4% m/m.  244 
NIR models included NIRM1 (modafinil lactose dilution), NIRM2 (modafinil 245 
excipients dilution), NIRM3 (modafinil excipients sequential addition), NIRM4 246 
(modafinil powdered tablets model) and NIRM5 (modafinil intact tablet model). 247 
NIRM1, NIRM2 and NIRM3 were constructed with a C: V ratio of 2:1, and had 248 
calibration ranges of 9.49 – 62.5, 15.4 – 52.9 and 15.9 – 62.5% m/m respectively. 249 
In addition, NIRM4 and NIRM5 were created with a C: V ratio of 3:1 and calibration 250 
range of 54.9 – 62.5% m/m respectively. 251 
The Raman models used were: RamanM1 (modafinil lactose dilution), RamanM2 252 
(modafinil excipients dilution), RamanM3 (modafinil excipients sequential addition), 253 
RamanM4 (modafinil powdered tablets model) and RamanM5 (modafinil intact 254 
tablet model). RamanM1, RamanM2 and RamanM3 were made with a C: V ratio 255 
of 2: 1, and had calibration range of 9.49 – 62.5, 15.4 – 52.9 and 15.9 – 62.5% 256 
m/m respectively. Furthermore, RamanM4 and RamanM5 were constructed with a 257 
C: V ratio of 3:1 and calibration range of 54.9 – 62.5% m/m respectively. 258 
 259 
3.3. PLSR model validation 260 
The linearity of the models was evaluated by internal validation criteria calculated 261 
using the calibration and internal validation sets. For internal validation, the criteria 262 
considered were the regression correlation coefficient (r2), root mean square error of 263 
calibration (RMSEC) and root mean square error of prediction (RMSEP) of the internal 264 
validation set. The r2 and RMSEC were calculated by interpreting the relationship 265 
between the predicted concentration and the nominal concentration of the calibration 266 
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set. Likewise, the RMSEP was calculated by interpreting the relationship between the 267 
predicted concentration and the nominal concentration of the validation set. If the 268 
model was a good fit, the relationship would be linear and an r2 value close to 1 would 269 
be obtained. There was no optimal value for the RMSEC and RMSEP however, the 270 
lower they were the more accurate was the model. A more accurate judgement was 271 
made by evaluating the relative standard error of prediction (RSEP); which was 272 
calculated as the percentage of the ratio of RMSEP to the mean value of the prediction 273 
set. A threshold value of ±5% was taken for RSEP. 274 
For FTIR models, the highest accuracy was observed for FTIRM1 (modafinil powdered 275 
tablet model), which showed r2 values of 0.98 and 0.97 for the calibration and 276 
validation sets respectively (Table 2). FTIRM1 also showed the high precision among 277 
the models with close RMSEC and RMSEP values, which were 0.52 and 0.78% m/m 278 
respectively. Moreover, the RSEP value of FTIRM4 was 1.33%. The worst model in 279 
relation to accuracy and precision among the FTIR models was FTIRM2. Thus, this 280 
model showed very low r2 values which were 0.51 and 0.49 for both the calibration 281 
and validation sets respectively. Moreover, the model showed high RMSEC, RMSEP 282 
and RSEP values of 11.2% m/m, 11.6% m/m and 29.8% respectively. This indicated 283 
that although the model was repeatable, it had low precision as the error values were 284 
not satisfactory. Similarly, FTIRM3 (modafinil excipients dilution) showed  close 285 
RMSEC and RMSEP values of 6.57 and 4.63% m/m respectively; yet, high RSEP 286 
value of 13.55%. FTIRM3 showed low accuracy of calibration with r2 value of 0.75. 287 
The same pattern was observed with FTIRM4 that had close values of RMSEC (6.29% 288 
m/m) and RMSEP (7.03% m/m) and high RSEP value (19.8%).  The lower accuracy 289 
in models based on mixtures rather than tablets could be attributed to the small amount 290 
of measurements (few milligrams) taken per sample. In this respect, the higher the 291 
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complexity of the sample (as the case of powdered tablets), the more representation 292 
of the sample was in the FTIR spectrum. 293 
NIR models showed the highest accuracy for NIRM3 (modafinil excipients sequential 294 
addition) which gave r2 values for the calibration and validation sets of 0.99 and 0.99 295 
respectively (Table 3). NIRM3 showed high precision with RMSEC and RMSEP values 296 
of 1.15 and 1.21 correspondingly. Moreover, it showed an RSEP value of 3.45%. 297 
Additionally, the two tablet based models showed high precision but slightly lower 298 
accuracy than NIRM3. These included NIRM4 (modafinil powdered tablet model) and 299 
NIRM5 (modafinil intact tablet model) which had r2 values of calibration of 0.77 and 300 
0.69 individually. Both models were highly precise and showed RMSEC values below 301 
2% m/m and RSEP values below 4%. The remaining two powder models (NIRM1 and 302 
NIRM2) showed slightly lower accuracy but very poor precision. Thus, the r2 values of 303 
calibration for NIRM1 (modafinil lactose dilution) and NIRM2 (modafinil excipients 304 
dilution) were 0.72 and 0.84. Both of these models showed good repeatability with 305 
very close RMSEC and RMSEP values. Thus, NIRM1 showed RMSEC and RMSEP 306 
values of 8.45 and 8.82% m/m respectively. Likewise, NIRM2 showed RMSEC and 307 
RMSEP values of 5.26 and 5.25% m/m but had very poor external precision in the 308 
range of 15 – 23%.  309 
Raman models showed the highest accuracy/precision for RamanM4 (modafinil 310 
powdered tablet model) and Raman M5 (modafinil intact tablet model) (Table 3). The 311 
aforementioned two models showed r2 value of calibration of 0.98 and 0.94. In 312 
addition, the RMSEC and RMSEP values for RamanM4 were 0.54 and 0.82% m/m, 313 
whereas for RamanM5 these values were 0.96 and 0.91% m/m respectively. 314 
RamanM4 provided a more precise model as it showed ten times lower RSEP value 315 
(1.4%) than RamanM5 (12.1%). The models based on powdered mixtures gave lower 316 
14 
 
accuracy and precision than tablet based models. In this sense, RamanM1 (modafinil 317 
lactose dilution), RamanM2 (modafinil excipients dilution) and RamanM3 (modafinil 318 
excipients sequential addition) had low r2 values of calibration which were 0.70, 0.84 319 
and 0.76 respectively. The three aforementioned models had high RSEP values which 320 
were in the range of 17 – 24%. All three models showed close agreement between 321 
their RMSEC and RMSEP values (Table 3). 322 
 323 
3.4. Prediction of modafinil in generic tablets 324 
Test sets of powdered and intact tablets were used to examine the external predictive 325 
ability of the models. The predicted value was converted into label claim and the 326 
percentage label claim of each product was assessed. The pharmacopoeia acceptable 327 
deviation of the API for tablets is usually ±5% of the label claim in order to allow 328 
variation in production, degradation during shelf life of the product and accuracy of the 329 
analytical method. In this work the range was extended to ±30% of the label claim to 330 
compensate for difficulty in setting up a calibration in the spectra and account for the 331 
noise generated by the instrument/spectral algorithms [16]. 332 
For powdered tablets, all the eight products were predicted through the powdered 333 
dilution models (Table 4). In this respect, the best predictive ability was observed for 334 
NIRM3 which showed a mean prediction of 98.2% label claim (RSD = 2.35%) for all 335 
batches. This was followed by FTIRM3 and NIRM1, which showed mean prediction 336 
values of 97.9 and 97.2% label claim respectively. Additionally, FTIRM2 and NIRM2 337 
showed good predictive ability with values of 91.1 and 90.2% label claim respectively. 338 
The remaining models (FTIRM1, RamanM1, RamanM2 and RamanM3) exhibited poor 339 
predictive ability below 70%. 340 
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RamanM2 and RamanM3 showed better prediction for intact tablets (Table 5). Thus, 341 
the mean prediction of intact tablets using the two models were 108 and 84% label 342 
claim respectively. Moreover, NIRM2 showed good predictive ability for intact tablets 343 
with a mean prediction of 103% label claim. The remaining models included NIRM1, 344 
NIRM3 and RamanM1 had poor prediction above 130% label claim. 345 
 346 
 347 
4. Conclusions 348 
The findings demonstrated that the combination of handheld FTIR, NIR and Raman 349 
spectroscopy with PLSR offered a rapid method for quantifying modafinil in branded 350 
generic medicines with minimal sample preparation. NIR and Raman techniques were 351 
non-destructive, however FTIR required powdering the tablets prior to measurement. 352 
In comparison to NIR, FTIR and Raman showed that models based on tablets were 353 
more accurate than those based on powder mixtures. Among the powder mixture 354 
models, modafinil excipients sequential addition offered the highest accuracy and 355 
precision for the quantification of powdered tablets using FTIR and NIR spectroscopy. 356 
Modafinil excipient dilution models offered the highest accuracy and precision for the 357 
quantification of intact tablets using NIR and Raman spectroscopy. Consequently, the 358 
choice of the powder model depended to a degree, on the technique used as well as 359 
the sample quantified. Subsequently, this may represent a challenge in the 360 
generalisability of the method to other nootropics that could be of different 361 
concentration and have different formulation. Hence, future work should consider the 362 
accuracy of quantification for different formulation types (tablets, capsules, caplets) 363 
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1 1a 100 57.6 
1 1b 100 62.9 
2 2a 200 65.9 
2 2b 200 72.7 
3 3a 200 63.8 
3 3b 200 66.3 
4 4a 100 57.7 
4 4b 100 62.8 
 489 















M1V1 201.3 LAC     0 201.3 62.5 
M1V2 181.6 LAC   19.6 201.2 56.4 
M1V3 168.5 LAC   32.6 201.1 52.4 
M1V4 159.5 LAC   43.3 202.8 49.1 
M1V5 151.2 LAC   53.1 204.3 46.2 
M1V6 129 LAC   71.7 200.7 40.2 
M1V7 110.9 LAC   90.6 201.5 34.4 
M1V8   99.3 LAC   98.9 198.2 31.3 
M1V9   81 LAC 119.9 201 25.2 
M1V10   71.8 LAC 129.7 201.5 22.3 
M1V11   50.8 LAC 150 200.8 15.8 
M1V12   30.6 LAC 170.7 201.3   9.5 
M1V13     0 LAC 199.6 199.6   0 
M2V1 169.6 LAC/ POV   30.6 200.2 52.9 
M2V2 163 LAC/POV/ MgS   52.4 215.4 47.3 
M2V3 121.9 LAC/ POV/ MgS/ MAI   79.4 201.3 37.8 
M2V4 104.1 LAC/POV/ MgS/MAI/ MCC   97.2 201.3 32.3 
M2V5   76.8 LAC/MCC/ NaCMC 134.9 211.7 22.7 
M2V6   51.8 LAC/POV/ MgS/MAI/ 
MCC/NaCMC 
158.9 210.7 15.4 
M3V1 201.3 0     0 201.3 62.5 
M3V2 180.3 LAC   43.2 223.5 50.1 
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M3V3 134.4 POV   78.8 213.1 39.4 
M3V4 100.7 MgS   97.2 197.8 31.8 
M3V5   87.2 MAI 128 215.2 25.3 
M3V6   71 MCC 149.1 220.1 20.2 
M3V7   52.7 NaCMC 154.5 207.2 15.9 
DN: dilution number, M1: modafinil lactose dilution, M2: modafinil excipients dilution, M3: modafinil 491 
excipients sequential addition, LAC: lactose, POV: povidone, MgS: magnesium stearate, MAI: maize 492 
starch, MCC: microcrystalline cellulose, NaCMC: sodium carboxymethylcellulose. 493 
 494 





r2calib RMSEC  
(% m/m) 




FTIRM1 3 25:11 0.98   0.52 0.97   0.78   1.33 
FTIRM2 1 12:60 0.51 11.24 0.49 11.61 29.9 
FTIRM3 1 14:70 0.75   6.57 0.93   4.63 16.5 
FTIRM4 4 60:20 0.84   6.29 0.80   7.03 19.8 
NIRM1 1 25:11 0.72   8.45 0.70   8.82 23.3 
NIRM2 1 12:60 0.84   5.26 0.84   5.25 15.2 
NIRM3 3 14:70 0.99   1.15 0.99   1.21   3.45 
NIRM4 1 60:20 0.77   1.77 0.69   2.05   3.51 
NIRM5 1 48:16 0.69   1.91 0.76   1.71   2.85 
RamanM1 1 25:11 0.70   8.49 0.80   6.74 19.0 
RamanM2 1 12:60 0.84   5.52 0.83   6.57 17.8 
RamanM3 1 14:70 0.76   7.62 0.83   9.16 23.9 
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RamanM4 4 60:20 0.98   0.54 0.95   0.82   1.40 
RamanM5 4 48:16 0.94   0.96 0.93   0.91 12.1 
FTIRM1, NIRM1and RamanM1: modafinil lactose dilution, FTIRM2, NIRM2 and RamanM2: modafinil 496 
excipients dilution, FTIRM3, NIRM3and RamanM3: modafinil excipients sequential addition, FTIRM4, 497 
NIRM4 and RamanM4: modafinil powdered tablets model, NIRM5 and RamanM5: modafinil intact tablet 498 
model. C:V: calibration:validation ratio, F: number of factors, r2: correlation coefficient, RMSE:root mean 499 








Predicted label claim (%) 
1a 1b 2a 2b 3a 3b 4a 4b 
Dose (mg) 100 100 200 200 200 200 100 100 
FTIRM1 24.9 57.7 49.4 43.8 70.2 49.4 28.1 42.6 
FTIRM2 98.5 96.4 86.8 87.8 88.0 87.5 91.2 92.9 
FTIRM3 105 104 93.1 94.1 94.6 93.9 98.4 100 
NIRM1 100 98.6 95.3 95.2 95.9 93.4 101 98.3 
NIRM2 92.0 89.5 88.8 88.4 89.6 87.1 94.4 91.4 
NIRM3 97.6 94.7 99.2 99.2 101 96.9 101 96.0 
RamanM1 91.1 60.7 55.4 55.8 56.0 55.2 59.1 60.6 
RamanM2 74.0 46.2 44.9 44.9 44.9 44.5 46.7 48.7 
RamanM3 80.6 65.9 64.0 63.2 65.8 64.0 67.5 68.4 
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BN: Batch number 505 
 506 




Predicted label claim (%)  
2a 2b 3a 3b 4a 4b  
Dose  
(mg) 
200 200 200 200 100 100  
NIRM1 134 135 137 136 133 133  
NIRM2 107 107 108 110 95.4 89.1  
NIRM3 144 145 148 150 125 118  
RamanM1 186 188 170 182 205 210  
RamanM2 101 106 97.6 104 119 122  
RamanM3 77.9 81.0 72.5 77.7 94.5 100.9  
BN: Batch number 508 
 509 
Figure legend 510 
Fig. 1. MSCD1 treated (a) FTIR spectrum modafinil tablets, (b) FTIR spectrum of pure 511 
modafinil, (c) FTIR spectrum lactose monohydrate, (d) NIR spectrum modafinil tablets, 512 
(e) NIR spectrum of pure modafinil, (f) NIR spectrum lactose monohydrate, (g) Raman 513 
spectrum modafinil tablets, (h) Raman spectrum of pure modafinil and (i) Raman 514 
spectrum lactose monohydrate measured using the Bruker Alpha FTIR, JDSU 515 
microNIR and Rigaku handheld Raman instruments respectively. 516 
